Abstract:Background: The recombinant human parathyroid hormone (1-34) (rhPTH[1-34]) teriparatide is the first anabolic agent approved by the US Food and Drug Administration for the treatment of osteoporosis in men and women. This study was conducted to provide support for marketing authorization of an agent biosimilar to teriparatide in China.Objective: The main aim of the present study was to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic parameters of rhPTH(1-34) after single and multiple subcutaneous doses in healthy Chinese subjects.Methods: Two open-label, randomized, single-center, dose-escalation studies were performed. In study 1, subjects were randomized to receive a single dose of rhPTH(1-34) (10, 20, 30, 40, 50, or 60 mu g) or a multiple dose of rhPTH(1-34) (10 and 20 mu g once daily for 7 consecutive days) to determine the safety profile and tolerability, as reflected by the incidence, intensity, and seriousness of the observed adverse events. In study 2, a single dose of rhPTH(1-34) (10, 20, or 40 mu g) and a multiple dose of rhPTH(1-34) (20 mu g) were administrated subcutaneously to investigate the pharmacokinetic and pharmacodynamic parameters.Results: Forty-two subjects completed study 1, and 30 subjects completed study 2. rhPTH(1-34) was well tolerated during the investigated single (10-60 mu g) and multiple (10-20 mu g once daily for 7 consecutive days) dose ranges. The most generally reported adverse events were erythema at the injection site and gastrointestinal reactions. After single and multiple subcutaneous administration of rhPTH(1-34), the drug was rapidly absorbed, with a T-max of 20 to 30 minutes, and rapidly cleared from the plasma, with a t(1/2), of 47.2 to 60.6 minutes. The mean C-max, AUC(0-t), and AUC(0-infinity), increased in proportion to the doses, whereas the t(1/2), total clearance, and T-max values were independent of the administered dose. No significant differences in pharmacokinetic parameters were noted by sex except for Tmax in the 10-mu g and 20-mu g single-dose groups. Compared with the baseline levels, no significant changes or dose-related significant effects were observed in serum calcium and phosphate levels.Conclusions: All rhPTH(1-34) doses appeared to be well tolerated in the population studied. Linear pharmacokinetic characteristics were displayed in the dose range studied. Chinese ClinicalTrials.gov identifier: ChiCTR-ONC-12002874. (C) 2014 Elsevier HS Journals, Inc. All rights reserved.

Preparation of a Novel Recombinant Human Parathyroid Hormone and Investigation of Its Nasal Drops

Nasal administration of a novel recombinant human parathyroid hormone (1-34) analog for the treatment of osteoporosis of ovariectomized rats.

A Novel Human Parathyroid Hormone (1-34) Analog for the Treatment of Osteoporosis

Study on preparation and activity of a novel recombinant human parathyroid hormone(1-34) analog with N-terminal Pro-Pro extension.

[The Study on the Inhibitive Effects of Recombinant Parathyroid Hormone (1-34) on Osteolysis in a Murine Calvarial Model Induced by Wear Particles].

Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis

Biosynthesis of A Novel Recombinant Peptide Derived from Hpth(1-34)

Impacts of the N-terminal Fragment Analog of Human Parathyroid Hormone on Structure, Composition and Biomechanics of Bone

Study on Preparation and Activity of A Novel Recombinant Human Parathyroid Hormone Analog Pro-Pro-[Arg11]-hPTH(1-34)-Pro-Pro

Development and in vivo evaluation of intranasal formulations of parathyroid hormone (1-34)

Pharmacological Effects of a Recombinant Hpth(1-34) Derived Peptide on Ovariectomized Rats.

Preliminary Evaluation of a Novel Oral Delivery System for Rhpth1-34: in Vitro and in Vivo

Large Scale Preparation of Recombinant Human Parathyroid Hormone 1–84 from Escherichia Coli

Therapeutic Effect of a Novel Recombinant Human Parathyroid Hormone Related Peptide on Osteoporosis in Ovariectomized Rats

Therapeutic Effect of Recombinant Human Parathyroid Hormone(1-34) on Osteoporosis of Ovariectomized Rats

A Randomized, Multicenter Controlled Trial to Compare the Efficacy of Recombinant Human Parathyroid Hormone (1-34) with Elcatonin in Postmenopausal Women with Osteoporosis in China.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Parathyroid Hormone (1-34) in Healthy Chinese Subjects

Dimeric PTH(1-34) Activates the Parathyroid Hormone-1 Receptor in vitro and Stimulates Bone Formation in Osteoporotic Female Mice

Parathyroid Hormone Derivative with Reduced Osteoclastic Activity Promoted Bone Regeneration Via Synergistic Bone Remodeling and Angiogenesis.

Self-Dissolving Microneedle Arrays for Transdermal Absorption Enhancement of Human Parathyroid Hormone (1-34)

Comparison Between Recombinant Human Parathyroid Hormone (1-34) and Elcatonin in Treatment of Primary Osteoporosis